Dupilumab Shows Benefits in Larger EoE Cohort : vimarsana.com

In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.

Related Keywords

Phoenix , Arizona , United States , Ohio , Cincinnati , Akron , American , Regeneron Sanofi , Marc Rothenberg , Brian Schroer , Eli Lilly , Serpin Pharm , Robarts Alimentiv , Evan Dellon , Ellodi Pharma , Revolo Biotherapeutics , Adare Ellodi , Glaxosmithkline , Amgen , Division Of Allergy , Mapi Research , American Academy Of Allergy , Teva Pharmaceuticals , American College Of Gastroenterology , Astrazeneca , University Of North Carolina At Chapel Hill , Bristol Myers Squibb , Cincinnati Children Hospital Medical Center , American Academy , Medscape Medical , American College , Dysphagia Symptom Questionnaire , Cincinnati Children , Hospital Medical Center , Akron Children , North Carolina , Chapel Hill , Gossamer Bio , Pulm One , Spoon Guru , Nextstone One , Mapi Research Trust , Annual Meeting , Otolaryngology , Nt Ears , Ose , Hroat , Eosinophilic Esophagitis , Dysphagia , Food Allergy , Asthma , Sthmatic , Remission , Adolescent Medicine , Allergy , Atopic Dermatitis , Dermatitis , Nasal Polyp , Biologic Therapy , Eosinophils , Osinophil Granulocytes , Esophagus , Esophageal , Monoclonal Antibody , Etuximab , Ituximab ,